Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-19 DNA vaccine - Entos Pharmaceuticals

Drug Profile

COVID-19 DNA vaccine - Entos Pharmaceuticals

Alternative Names: COVID-2019 DNA vaccine - Entos Pharmaceuticals; SARS-COV-2 vaccine - Entos Pharmaceuticals

Latest Information Update: 24 Mar 2020

At a glance

  • Originator Entos Pharmaceuticals
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 20 Mar 2020 Entos Pharmaceuticals plans preclinical trials in COVID-2019 infections (Prevention)
  • 19 Mar 2020 COVID-19 DNA vaccine is available for licensing as of 19 Mar 2020. www.entospharma.com
  • 19 Mar 2020 Early research in COVID-2019 infections (Prevention) in Canada (Parenteral)

Development Overview

Introduction

A plasmid DNA vaccine that encodes multiple antigens from the SARS-CoV-2 proteins and delivered by the fusogenix proteo-lipid vehicle is being developed by Entos Pharmaceuticals for prevention from the COVID-2019 infections. The proprietary fusogenix consists of neutral lipids and Fusion-Associated Small Transmembrane proteins (FAST) that enables efficient delivery of the plasmid DNA payload directly inside the cell. The plasmid DNA will encode selective antigens against which immune response will be induced. Fusogenix provides several advantages over traditional vaccines such as broad distribution due to its favorable tolerability, dose repetition, vaccine stability, production and ability to stimulate both B- and T-cell responses. Early stage development is ongoing in Canada.

Entos Pharmaceuticals is seeking collaborative opportunities for further development of their COVID-19 DNA vaccine [1] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class DNA vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7B (Combinations of Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research Canada Parenteral / unspecified Entos Pharmaceuticals 19 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Entos Pharmaceuticals Originator Canada
Entos Pharmaceuticals Owner Canada

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Entos Pharmaceuticals COVID 2019 infections Unspecified - 19 Mar 2020

Development History

Event Date Update Type Comment
20 Mar 2020 Trial Update Entos Pharmaceuticals plans preclinical trials in COVID-2019 infections (Prevention) [1] Updated 24 Mar 2020
19 Mar 2020 Licensing Status COVID-19 DNA vaccine is available for licensing as of 19 Mar 2020. www.entospharma.com [1] Updated 24 Mar 2020
19 Mar 2020 Phase Change Early research in COVID-2019 infections (Prevention) in Canada (Parenteral) [1] Updated 24 Mar 2020

References

  1. Entos Pharmaceuticals Is Developing a DNA Vaccine Against COVID-19 Using Its Fusogenix Nanomedicine Platform.

    Media Release
Back to top